NOVEL MASS-SCALE BIOSYNTHESIS: TAILORING CHEMICAL LOGIC & BIOSYNTHESIS

新颖的大规模生物合成：定制化学逻辑

• 批准号: IM230100534
• 负责人: A/Prof Tony Velkov
• 金额: $ 60.23万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Mid-Career Industry Fellowships
• 财政年份: 2023
• 资助国家: 澳大利亚
• 起止时间: 2023-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/IM230100534
• 关键词: NOVEL; MASS; SCALE; BIOSYNTHESIS; TAILORING

No new antibiotics against Gram-negative ‘superbugs’ are expected to be available in the near future. We have exhausted the chemical space from the natural product pool and lack a fundamental understanding of antibiotics in nature, this is a major hurdle for antibiotic design targeting bacterial resistance. This proposal aims to engineer unique chemo-enzymatic platforms for the synthesis of new lipopeptide scaffolds which will significantly expand the chemical space available for novel antibiotic discovery. The development of these unique platforms will greatly expand our inventory of natural product antibiotics and will represent a major technological break-through for Australia's biotechnology and pharmaceutical manufacturing sectors.

预计在不久的将来不会有针对革兰氏阴性“超级细菌”的新抗生素问世。我们已经从天然产物池中耗尽了化学空间，并且对自然界中的抗生素缺乏基本的了解，这是针对细菌耐药性的抗生素设计的主要障碍。该提案旨在设计独特的化学酶平台，用于合成新的脂肽支架，这将大大扩大新抗生素发现的化学空间。这些独特平台的开发将大大扩大我们的天然产物抗生素库存，并将代表澳大利亚生物技术和制药制造部门的重大技术突破。